Amplia Therapeutics Ltd. (AU:ATX) has released an update.
Amplia Therapeutics has successfully completed a share allotment, raising a significant $13 million in a capital initiative that included a Director Placement approved by shareholders. The funds will support the company’s ongoing development of innovative cancer therapies, including their advanced trials of the promising drug narmafotinib. This move highlights Amplia’s strategic efforts to strengthen its position in the pharmaceutical market.
For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.